Rules-Based Medicine Newswire (Page 4)

Rules-Based Medicine Newswire (Page 4)

Comprehensive Real-Time News Feed for Rules-Based Medicine. (Page 4)

Results 61 - 80 of 1,100 in Rules-Based Medicine

  1. Myriad Genetics, Inc. (MYGN) Receives Average Recommendation of "Hold" from BrokeragesRead the original story w/Photo

    Oct 4, 2017 | IntersportsWire

    Myriad Genetics, Inc. has been assigned an average recommendation of "Hold" from the thirteen analysts that are currently covering the stock, MarketBeat reports. Two equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and two have assigned a buy rating to the company.

    Comment?

  2. Myriad Genetics, Inc. Expected to Post Q1 2018 Earnings of $0.20 Per ShareRead the original story w/Photo

    Oct 3, 2017 | AmericanBankingNews.com

    Myriad Genetics, Inc. - Equities researchers at Leerink Swann issued their Q1 2018 earnings per share estimates for shares of Myriad Genetics in a report released on Monday. Leerink Swann analyst P. Souda anticipates that the company will post earnings per share of $0.20 for the quarter.

    Comment?

  3. Myriad Genetics, Inc. (MYGN) Given "Market Perform" Rating at Leerink SwannRead the original story w/Photo

    Oct 3, 2017 | IntersportsWire

    Leerink Swann currently has a $31.00 price objective on the stock. Leerink Swann also issued estimates for Myriad Genetics' Q1 2018 earnings at $0.20 EPS, Q2 2018 earnings at $0.26 EPS, Q3 2018 earnings at $0.26 EPS, Q4 2018 earnings at $0.31 EPS, Q1 2019 earnings at $0.26 EPS, Q2 2019 earnings at $0.28 EPS, Q3 2019 earnings at $0.29 EPS, Q4 2019 earnings at $0.30 EPS and FY2019 earnings at $1.13 EPS.

    Comment?

  4. Myriad Genetics, Inc. (MYGN) Now Covered by Analysts at Leerink SwannRead the original story w/Photo

    Oct 2, 2017 | AmericanBankingNews.com

    The firm set a "market perform" rating and a $31.00 price target on the stock. Leerink Swann's target price suggests a potential downside of 14.32% from the company's previous close.

    Comment?

  5. Head to Head Survey: WaferGen Bio-systemsRead the original story w/Photo

    Sep 27, 2017 | AmericanBankingNews.com

    WaferGen Bio-systems and Myriad Genetics are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, dividends, risk and earnings. Myriad Genetics has higher revenue and earnings than WaferGen Bio-systems.

    Comment?

  6. Myriad Genetics' (MYGN) Overweight Rating Reiterated at StephensRead the original story w/Photo

    Sep 25, 2017 | Daily Political

    Stephens currently has a $40.00 price target on the stock, up from their previous price target of $36.00. Other equities research analysts also recently issued research reports about the company.

    Comment?

  7. Myriad Genetics, Inc. (MYGN) Given "Overweight" Rating at StephensRead the original story w/Photo

    Sep 23, 2017 | IntersportsWire

    The firm currently has a $40.00 price objective on the stock, up from their prior price objective of $36.00. A number of other research analysts also recently weighed in on the stock.

    Comment?

  8. Myriad Genetics, Inc. (MYGN) Expected to Post Quarterly Sales of $182.22 MillionRead the original story w/Photo

    Sep 22, 2017 | IntersportsWire

    Wall Street analysts expect Myriad Genetics, Inc. to report sales of $182.22 million for the current quarter, according to Zacks Investment Research . Five analysts have made estimates for Myriad Genetics' earnings, with the lowest sales estimate coming in at $181.80 million and the highest estimate coming in at $183.02 million.

    Comment?

  9. Myriad Genetics' (MYGN) "Overweight" Rating Reiterated at StephensRead the original story w/Photo

    Sep 22, 2017 | AmericanBankingNews.com

    's stock had its "overweight" rating reissued by research analysts at Stephens in a research report issued on Friday, The Fly reports. They currently have a $40.00 price objective on the stock, up from their prior price objective of $36.00.

    Comment?

  10. Myriad Genetics, Inc. (MYGN) Reaches New 52-Week High at $33.73Read the original story w/Photo

    Sep 21, 2017 | The Breeze

    Myriad Genetics, Inc. shares reached a new 52-week high during mid-day trading on Thursday . The stock traded as high as $33.73 and last traded at $33.73, with a volume of 291,097 shares traded.

    Comment?

  11. Head-To-Head Analysis: Varex ImagingRead the original story w/Photo

    Sep 21, 2017 | IntersportsWire

    VAREX IMAGING and Myriad Genetics are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, risk, valuation, earnings, institutional ownership, analyst recommendations and profitability. This is a breakdown of recent ratings and target prices for VAREX IMAGING and Myriad Genetics, as reported by MarketBeat.com.

    Comment?

  12. State of Tennessee Treasury Department Decreases Position in Myriad Genetics, Inc.Read the original story w/Photo

    Sep 21, 2017 | IntersportsWire

    State of Tennessee Treasury Department cut its holdings in shares of Myriad Genetics, Inc. by 1.6% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission . The firm owned 64,075 shares of the company's stock after selling 1,050 shares during the period.

    Comment?

  13. Myriad Genetics, Inc. (MYGN) Holdings Reduced by Principal Financial Group Inc.Read the original story w/Photo

    Sep 21, 2017 | The Breeze

    Principal Financial Group Inc. reduced its position in Myriad Genetics, Inc. by 0.3% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 528,346 shares of the company's stock after selling 1,802 shares during the period.

    Comment?

  14. Myriad Genetics, Inc. (MYGN) Short Interest Down 12.9% in AugustRead the original story w/Photo

    Sep 19, 2017 | The Breeze

    Myriad Genetics, Inc. was the target of a large decrease in short interest in August. As of August 31st, there was short interest totalling 16,412,692 shares, a decrease of 12.9% from the August 15th total of 18,843,047 shares.

    Comment?

  15. Brokerages Expect Myriad Genetics, Inc. (MYGN) Will Post Quarterly Sales of $182.22 MillionRead the original story w/Photo

    Sep 18, 2017 | AmericanBankingNews.com

    Brokerages expect Myriad Genetics, Inc. to post sales of $182.22 million for the current fiscal quarter, according to Zacks Investment Research . Five analysts have issued estimates for Myriad Genetics' earnings, with the lowest sales estimate coming in at $181.80 million and the highest estimate coming in at $183.02 million.

    Comment?

  16. Myriad Genetics' (MYGN) Hold Rating Reaffirmed at Cowen and CompanyRead the original story w/Photo

    Sep 17, 2017 | AmericanBankingNews.com

    's stock had its "hold" rating reiterated by analysts at Cowen and Company in a research note issued on Sunday. They presently have a $25.00 target price on the stock.

    Comment?

  17. Varex Imaging (VREX) versus Myriad Genetics (MYGN) Financial ReviewRead the original story w/Photo

    Sep 16, 2017 | AmericanBankingNews.com

    Varex Imaging and Myriad Genetics are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, risk, valuation, analyst recommendations and institutional ownership. 91.8% of Varex Imaging shares are held by institutional investors.

    Comment?

  18. Myriad Genetics Announces Positive Data Supporting New riskScore Test ...Read the original story

    Sep 15, 2017 | PressReleasePoint

    Myriad Genetics , Inc. , a leader in molecular diagnostics and personalized medicine, today announced that two important studies will be featured in podium presentations at the 36th annual conference of the National Society of Genetic Counselors in Columbus, OH. We look forward to presenting our pioneering research at NSGC this year and bringing forward new innovations that are changing how a woman's risk of breast cancer is being managed and improving the lives of even more people, " said Johnathan Lancaster, M.D., Ph.D., chief medical officer, Myriad Genetics.

    Comment?

  19. Myriad Genetics Announces Positive Data Supporting New riskScorea ...Read the original story

    Sep 15, 2017 | Customer Interaction Solutions

    Myriad Genetics , Inc. , a leader in molecular diagnostics and personalized medicine, today announced that two important studies will be featured in podium presentations at the 36th annual conference of the National Society of Genetic Counselors in Columbus, OH. "We look forward to presenting our pioneering research at NSGC this year and bringing forward new innovations that are changing how a woman's risk of breast cancer is being managed and improving the lives of even more people," said Johnathan Lancaster, M.D., Ph.D., chief medical officer, Myriad Genetics.

    Comment?

  20. Myriad Genetics, Inc. (MYGN) Shares Sold by Pacad Investment Ltd.Read the original story w/Photo

    Sep 15, 2017 | The Breeze

    Pacad Investment Ltd. reduced its stake in Myriad Genetics, Inc. by 73.8% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission . The institutional investor owned 6,400 shares of the company's stock after selling 18,000 shares during the period.

    Comment?